(NASDAQ: SVRA) Savara's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.32%.
Savara's revenue in 2026 is $0.On average, 10 Wall Street analysts forecast SVRA's revenue for 2026 to be $2,930,695,386, with the lowest SVRA revenue forecast at $1,037,204,205, and the highest SVRA revenue forecast at $7,360,097,637. On average, 8 Wall Street analysts forecast SVRA's revenue for 2027 to be $15,558,267,731, with the lowest SVRA revenue forecast at $11,432,167,894, and the highest SVRA revenue forecast at $20,789,108,748.
In 2028, SVRA is forecast to generate $34,756,983,055 in revenue, with the lowest revenue forecast at $28,559,953,985 and the highest revenue forecast at $44,013,641,735.